Traumatic Brain Injury: Six Psychedelics Companies Target $120 Billion Market

 A Data Bridge research report estimated TBI to be roughly a $120 billion treatment market (2019), estimated to reach $182 billion by 2027. It’s the largest individual medical treatment market currently targeted by psychedelics-based R&D.

Psychedelics R&D takes aim at TBI market

Few medical experts are more well-versed on the subject of Traumatic Brain Injury than renowned neuroscientist, Dr. Dan Engle.

Author of The Concussion Repair Manual, much of Dr. Engle’s career has focused on TBI. But medical science still has few effective therapies to address the long-term effects of TBI. Dr. Engle’s research into new therapies for TBI led him (not surprisingly) to psychedelic drugs.

This isn’t a recent pivot for Dr. Engle. As far back as 2015, Engle was a regular guest on such psychedelics-oriented programs as The Joe Rogan Experience and The Tim Ferriss Show – discussing the potential of psychedelics-based medicine.

What is recent for Dr. Engle is the opportunity to lead his own clinical research into finding an effective psychedelics-related treatment for TBI. On February 17th, Mind Cure Health (CAN: MCUR / US: MCURF) named Dr. Engle to lead its own R&D program for TBI.

While much of the psychedelics research aimed at TBI focuses on psilocybin-based treatments, MINDCURE is targeting synthetic ibogaine for their own R&D.

In addition to the appointment of Dr. Engle, MINDCURE has made several additional moves aimed at advancing its TBI research and MCUR’s general R&D initiatives.

February 16th: completed beta testing of its PsyCollage bioinformatics platform, a key tool for data aggregation and processing.

March 3rd: announced manufacturing of the synthetic ibogaine to be used in its clinical research

March 4th: announced that PsyCollage had identified ibogaine indications that support neuroregenerative pathways.

As MINDCURE pushes forward on its pre-clinical research, several other companies are advancing psychedelics-based research initiatives aimed at this market.

Wesana Health is a private company that has announced plans for TBI research but came to this field via an entirely different road.

View single page >> |

Disclaimer: The writer holds shares in Mind Cure Health. Mind Cure Health is a client of Psychedelic Stock Watch.

How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.
James Hunter 1 month ago Member's comment

Thanks for sharing: RVV mentioned in article: "Revive Therapeutics (CAN: RVV / US: $RVVTF) plans to seek IND status from the FDA in Q2 2021, for its psilocybin-based research on TBI. With a different (non-psychedelic) drug already in a Phase III clinical trial, Revive has more experience in formal clinical research. But TBI is not the principal focus of its R&D."

James Hunter 1 month ago Member's comment

Bright future for psychedelics TBI R&D

With a half-dozen companies in the psychedelics industry already with announced plans for TBI-related research, some investors may see this R&D niche as crowded.

But with a huge treatment population and an equally huge treatment market to target (estimated to reach $182 billion by 2027), there are more than enough revenue dollars on the table for second- and third-place finishers in this derby to be well-rewarded by the market.